TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacture and sale of cancer detection devices and systems. The firm offers AI-enabled device, namely TruScreen a cervical cancer screening device that detects precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. TruScreen uses, opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable single use sensor, a handheld device (HHD), and an intelligent cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up and discomfort, and the need for supporting laboratory infrastructure, as well as problems associated with human papillomavirus (HPV) tests.
Truscreen Group (ASX: TRU)
- Home
- Truscreen Group (ASX: TRU)
Here are the latest articles on Truscreen Group (ASX: TRU)
Cheaper pap smears for Saudi women as TruScreen gets reimbursement approval from insurers
February 12, 2024
In a much-needed and laudable development for women’s healthcare in Saudi Arabia, medical devices company TruScreen’s (ASX: TRU) distributor, Bettalife, has successfully obtained reimbursement approval from the majority of private health insurance companies in the country. With reimbursement in place, women who are insured and opt for TruScreen over the conventional Pap Smear will receive
TruScreen establishes cervical screening centre in Mexico to improve early diagnosis
August 3, 2022
Honestly, there’s very little reason to leave Australia. We literally have it all: snow capped mountains, white sandy beaches, awesome cities, excellent coffee and the pièce de résistance – universal healthcare. Our healthcare system isn’t perfect by any means, but when you look at other countries, we have a lot to be grateful for with
Truscreen expands market for real time digital diagnostic testing device
July 1, 2021
Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time. Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test
Recent Articles
